D
David P. Kelsen
Researcher at Cornell University
Publications - 89
Citations - 6680
David P. Kelsen is an academic researcher from Cornell University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 41, co-authored 89 publications receiving 6065 citations. Previous affiliations of David P. Kelsen include University of Pittsburgh & Kettering University.
Papers
More filters
Journal ArticleDOI
Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting
Richard J. Gralla,Loretta M. Itri,Sharon E. Pisko,Anna E. Squillante,David P. Kelsen,David W. Braun,Laurie A. Bordin,Thomas J. Braun,Charles W. Young +8 more
TL;DR: It is concluded that metoclopramide in high intravenous doses has greater antiemetic activity than placebo or prochlorperazine in patients receiving cisplatin chemotherapy in patients with advanced cancer.
Journal ArticleDOI
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Manish A. Shah,Ramesh K. Ramanathan,David H. Ilson,Alissa Levnor,David R. D'Adamo,Eileen M. O'Reilly,Archie Tse,Robin Trocola,Lawrence H. Schwartz,M. Capanu,Gary K. Schwartz,David P. Kelsen +11 more
TL;DR: Bvacizumab can be safely given with chemotherapy even with primary gastric and GEJ tumors in place, with response rate, time to disease progression (TTP), and overall survival are encouraging, with TTP improved over historical controls by 75%.
Journal ArticleDOI
Hypermethylated APC DNA in Plasma and Prognosis of Patients With Esophageal Adenocarcinoma
Kazuyuki Kawakami,Jan Brabender,Reginald V. Lord,Susan Groshen,Bruce D. Greenwald,Mark J. Krasna,Jing Yin,A. Steven Fleisher,John M. Abraham,David G. Beer,David Sidransky,Harold T. Huss,Tom R. DeMeester,Cindy A. Eads,Peter W. Laird,David H. Ilson,David P. Kelsen,David H. Harpole,Mary Beth H. Moore,Kathleen D. Danenberg,Peter V. Danenberg,Stephen J. Meltzer,Stephen J. Meltzer +22 more
TL;DR: Levels of hypermethylated APC gene DNA in the plasma may be a useful biomarker of biologically aggressive disease in esophageal adenocarcinoma patients and should be evaluated as a potential biomarker in additional tumor types.
Journal ArticleDOI
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.
Richard J. Gralla,Ephraim S. Casper,David P. Kelsen,David W. Braun,Mary E. Dukeman,Nael Martini,Charles W. Young,Robert B. Golbey +7 more
TL;DR: A combination of new agents with high dose cisplatin and vindesine supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.
Journal ArticleDOI
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin
Mark G. Kris,Richard J. Gralla,Rebecca A. Clark,Leslie B. Tyson,Joe O'Connell,Michael S. Wertheim,David P. Kelsen +6 more
TL;DR: The highest nausea and vomiting scores were seen during the period from 48 to 72 hours after administration of cisplatin, with acceptable correlation between patient scores and observer ratings.